Scandion Oncology A/S (SCOL.ST)

SEK 0.08

(-6.78%)

Long Term Debt Summary of Scandion Oncology A/S

  • Scandion Oncology A/S's latest annual long term debt in 2023 was - DKK , down -100.0% from previous year.
  • Scandion Oncology A/S's latest quarterly long term debt in 2024 Q2 was - DKK , down 0.0% from previous quarter.
  • Scandion Oncology A/S reported annual long term debt of 821 Thousand DKK in 2022, up 64.2% from previous year.
  • Scandion Oncology A/S reported annual long term debt of 500 Thousand DKK in 2021, down 0.0% from previous year.
  • Scandion Oncology A/S reported quarterly long term debt of - DKK for 2024 Q1, down 0.0% from previous quarter.
  • Scandion Oncology A/S reported quarterly long term debt of 603 Thousand DKK for 2023 Q2, down -13.98% from previous quarter.

Annual Long Term Debt Chart of Scandion Oncology A/S (2023 - 2017)

Historical Annual Long Term Debt of Scandion Oncology A/S (2023 - 2017)

Year Long Term Debt Long Term Debt Growth
2023 - DKK -100.0%
2022 821 Thousand DKK 64.2%
2021 500 Thousand DKK 0.0%
2020 - DKK 0.0%
2019 - DKK 0.0%
2018 - DKK 0.0%
2017 - DKK 0.0%

Peer Long Term Debt Comparison of Scandion Oncology A/S

Name Long Term Debt Long Term Debt Difference
Lipum AB (publ) 1.76 Million SEK 100.0%
Alligator Bioscience AB (publ) 7.51 Million SEK 100.0%
Modus Therapeutics Holding AB (publ) - SEK NaN%
BioArctic AB (publ) 2.15 Million SEK 100.0%
Sprint Bioscience AB (publ) - SEK NaN%
Mendus AB (publ) 850 Thousand SEK 100.0%
Intervacc AB (publ) 142 Thousand SEK 100.0%
QuiaPEG Pharmaceuticals Holding AB (publ) - SEK NaN%
Active Biotech AB (publ) 3 Million SEK 100.0%
Magle Chemoswed Holding AB (publ) 32.58 Million SEK 100.0%
Bio-Works Technologies AB (publ) - SEK NaN%
Aptahem AB (publ) - SEK NaN%
Vicore Pharma Holding AB (publ) - SEK NaN%
Kancera AB (publ) - SEK NaN%
Infant Bacterial Therapeutics AB (publ) - SEK NaN%
Fluicell AB (publ) - SEK NaN%
Saniona AB (publ) 65.23 Million SEK 100.0%
Lipigon Pharmaceuticals AB (publ) - SEK NaN%
Biovica International AB (publ) 4.29 Million SEK 100.0%
Spago Nanomedical AB (publ) - SEK NaN%
AcouSort AB (publ) - SEK NaN%
Xintela AB (publ) - SEK NaN%
Ziccum AB (publ) 286 Thousand SEK 100.0%
Genovis AB (publ.) 74.8 Million SEK 100.0%
Abliva AB (publ) 424 Thousand SEK 100.0%
Egetis Therapeutics AB (publ) 103.4 Million SEK 100.0%
Karolinska Development AB (publ) - SEK NaN%
OncoZenge AB (publ) - SEK NaN%
CombiGene AB (publ) - SEK NaN%
Camurus AB (publ) 13.61 Million SEK 100.0%
Corline Biomedical AB - SEK NaN%
Amniotics AB (publ) - SEK NaN%
IRLAB Therapeutics AB (publ) 24.51 Million SEK 100.0%
2cureX AB (publ) - SEK NaN%
Asarina Pharma AB (publ) 1 Million SEK 100.0%
Calliditas Therapeutics AB (publ) 939.5 Million SEK 100.0%
Xspray Pharma AB (publ) 31.94 Million SEK 100.0%
Elicera Therapeutics AB (publ) - SEK NaN%
Isofol Medical AB (publ) - SEK NaN%
Stayble Therapeutics AB (publ) 850 Thousand SEK 100.0%
I-Tech AB - SEK NaN%
Hansa Biopharma AB (publ) 844.9 Million SEK 100.0%
Cyxone AB (publ) 74 Thousand SEK 100.0%
ExpreS2ion Biotech Holding AB (publ) 1.43 Million SEK 100.0%
Biosergen AB - SEK NaN%
Cantargia AB (publ) - SEK NaN%
NextCell Pharma AB - SEK NaN%
Nanologica AB (publ) 136 Thousand SEK 100.0%
SynAct Pharma AB 58 Thousand SEK 100.0%
Annexin Pharmaceuticals AB (publ) - SEK NaN%
LIDDS AB (publ) - SEK NaN%
BioInvent International AB (publ) 14.53 Million SEK 100.0%
Alzinova AB (publ) 800 Thousand SEK 100.0%
Oncopeptides AB (publ) 106.48 Million SEK 100.0%
Guard Therapeutics International AB (publ) - SEK NaN%
Pila Pharma AB (publ) - SEK NaN%
Scandinavian ChemoTech AB (publ) - SEK NaN%
Simris Alg AB (publ) 90.74 Million SEK 100.0%
Diamyd Medical AB (publ) 30.67 Million SEK 100.0%
Xbrane Biopharma AB (publ) 112.89 Million SEK 100.0%
Ascelia Pharma AB (publ) 176 Thousand SEK 100.0%
Diagonal Bio AB (publ) - SEK NaN%